# Karyopharm Therapeutics Inc. (KPTI) · Edgar & Edgarette company card

> Karyopharm Therapeutics (KPTI) grew revenue 0.6% in FY2025 to $146 million, operating margin -62.1% against a -3.8% median for pharmaceutical preparations, equity -270% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1503802 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/KPTI) · [JSON](https://www.pops4.com/boards/company/KPTI.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $146M |
| Revenue growth, 1 year | 0.6% |
| Revenue growth per year | -8.7% |
| Operating margin | -62.1% (prior year -82.2%) |
| Net margin | -134.2% |
| Operating cash flow | −$75M |
| Capital spending | $0 |
| Free cash flow | −$75M |
| Cash | $61M |
| Long-term debt | — |
| Total assets | $108M |
| Total equity | −$293M |
| Equity ÷ assets | -270.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -58.62 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed bankruptcy or receivership, debt accelerated or triggered in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -62.1% in FY2025
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $146.1M (FY2025). Experience: revenue up 0.6% on the year, down 8.7% a year over 4 years; operating margin -62.1%, up from -82.2%. Soundness: equity -270.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $116.5M and $173.1M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $105.4M to $192.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -62.1% against a -3.8% median; growth 0.6% against 13.7%.

Range logged 2026-09-24, receipt 78cd583d5b886a8b, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 1.03 Bankruptcy or receivership: 1, latest 2026-11-03 ([filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/0001193125-26-444164-index.htm))
- Item 2.04 Debt accelerated or triggered: 2, latest 2026-11-03 ([filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/0001193125-26-444164-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-07-17 ([filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526307964/0001193125-26-307964-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 1.01 Entry into a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 2.03 Creation of a Direct Financial Obligation; 2.04 Triggering Events That Accelerate a Financial Obligation; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/0001193125-26-444164-index.htm)
- 8-K · filed 2026-11-02 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526442822/0001193125-26-442822-index.htm)
- 8-K · filed 2026-10-22 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526428938/0001193125-26-428938-index.htm)
- 8-K · filed 2026-10-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526421025/0001193125-26-421025-index.htm)
- 8-K · filed 2026-09-18 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/0001193125-26-395517-index.htm)
- 8-K · filed 2026-09-11 · 1.01 Entry into a Material Definitive Agreement; 2.04 Triggering Events That Accelerate a Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1503802/000119312526388621/0001193125-26-388621-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001503802.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1503802

## Cite

POPS4, Edgar & Edgarette: Karyopharm Therapeutics Inc. (KPTI) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/KPTI. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.